Erratum: Sitagliptin reduces cardiac apoptosis, hypertrophy and fibrosis primarily by insulin-dependent mechanisms in experimental type-II diabetes. Potential roles of GLP-1 isoforms (PLoS ONE (2013) 8:10 (e78330) DOI:10.1371/journal.pone.0078330);Sitagliptin Reduces Cardiac Apoptosis, Hypertrophy and Fibrosis Primarily by Insulin-Dependent Mechanisms in Experimental type-II Diabetes. Potential Roles of GLP-1 Isoforms

PLoS ONE

Volumn 8, Issue 10, 2013, Pages

  Picatoste, Belén ^a   Ramírez, Elisa ^a   Caro Vadillo, Alicia ^b   Iborra, Cristian ^a   Egido, Jesús ^a   Tuñón, José ^a   Lorenzo, Óscar ^a  

^a 28400 Madrid   (Spain)

^b UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCAGON LIKE PEPTIDE; GLUCAGON LIKE PEPTIDE 1; GLUCAGON LIKE PEPTIDE 1 RECEPTOR; GLUCAGON LIKE PEPTIDE 1 [9-36]; GLUCOSE; INSULIN; METFORMIN; PALMITIC ACID; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR DELTA; SITAGLIPTIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CELL DEATH; CONTROLLED STUDY; DRUG EFFECT; FIBROBLAST CULTURE; HEART CELL CULTURE; HEART LEFT VENTRICLE; HEART MUSCLE CELL; HEART MUSCLE FIBROSIS; HEART PROTECTION; HEART VENTRICLE HYPERTROPHY; HORMONE BLOOD LEVEL; HYPERGLYCEMIA; HYPERLIPIDEMIA; IN VITRO STUDY; MALE; MORNING DOSAGE; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; RAT; SIGNAL TRANSDUCTION; UPREGULATION;

RATTUS;

ANIMALS; APOPTOSIS; CARDIOMEGALY; CARDIOTONIC AGENTS; CELLS, CULTURED; DIABETES MELLITUS, TYPE 2; DIABETIC CARDIOMYOPATHIES; DISEASE MODELS, ANIMAL; DRUG EVALUATION, PRECLINICAL; FIBROBLASTS; FIBRONECTINS; FIBROSIS; GLUCAGON-LIKE PEPTIDE 1; GLUCOSE INTOLERANCE; HYPOGLYCEMIC AGENTS; INSULIN; MALE; METFORMIN; MYOCARDIUM; MYOCYTES, CARDIAC; PPAR DELTA; PROTEIN ISOFORMS; PYRAZINES; RATS; TRIAZOLES;

EID: 84886900737     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0091601     Document Type: Erratum

References (55)

1. American Diabetes Association (2009) Standards of medical care in diabetes. Diabetes Care, 32 (Suppl 1):: S13-S61. doi:10.2337/dc09-S013. PubMed: 19118286.
2. Aneja A, Tang WHW, Bansilal S, Garcia MJ, Farkouh ME, (2008) Diabetic cardiomyopathy: insights into pathogenesis, diagnostic challenges, and therapeutic options. Am J Med, 121: 748-757. doi:10.1016/j.amjmed.2008.03.046. PubMed: 18724960.
3. Chen S, Evans T, Mukherjee K, Karmazyn M, Chakrabarti S, (2000) Diabetes-induced myocardial structural changes: role of endothelin-1 and its receptors. J Mol Cell Cardiol, 32: 1621-1629. doi:10.1006/jmcc.2000.1197. PubMed: 10966825.
4. Mizushige K, Yao L, Noma T, Kiyomoto H, Yu Y, et al. (2000) Alteration in left ventricular diastolic filling and accumulation of myocardial collagen at insulin-resistant prediabetic stage of a type II diabetic rat model. Circulation, 101: 899-907. doi:10.1161/01.CIR.101.8.899. PubMed: 10694530.
5. Drucker DJ, (2007) Dipeptidyl peptidase-4 inhibition and the treatment of type 2 diabetes: preclinical biology and mechanisms of action. Diabetes Care, 30: 1335-1343. doi:10.2337/dc07-0228. PubMed: 17337495.
6. Nikolaidis LA, Mankad S, Sokos GG, Miske G, Shah A, et al. (2004) Effects of glucagon-like peptide-1 in patients with acute myocardial infarction and left ventricular dysfunction after successful reperfusion. Circulation, 109: 962-965. doi:10.1161/01.CIR.0000120505.91348.58. PubMed: 14981009.
7. Sokos GG, Nikolaidis LA, Mankad S, Elahi D, Shannon RP, (2006) Glucagon-like peptide-1 infusion improves left ventricular ejection fraction and functional status in patients with chronic heart failure. J Card Fail, 12: 694-699. doi:10.1016/j.cardfail.2006.08.211. PubMed: 17174230.
8. Ban K, Noyan-Ashraf MH, Hoefer J, Bolz S-S, Drucker DJ, et al. (2008) Cardioprotective and vasodilatory actions of glucagon-like peptide 1 receptor are mediated through both glucagon-like peptide 1 receptor-dependent and-independent pathways. Circulation, 117: 2340-2350. doi:10.1161/CIRCULATIONAHA.107.739938. PubMed: 18427132.
9. Mudaliar S, Henry RR, (2012) The incretin hormones: from scientific discovery to practical therapeutics. Diabetologia, 55: 1865-1868. doi:10.1007/s00125-012-2561-x. PubMed: 22555471.
10. Hui H, Tang YG, Zhu L, Khoury N, Hui Z, et al. (2010) Glucagon like peptide-1-directed human embryonic stem cells differentiation into insulin-producing cells via hedgehog, cAMP, and PI3K pathways. Pancreas, 39: 315-322. doi:10.1097/MPA.0b013e3181bc30dd. PubMed: 19924023.
11. Glauser DA, Brun T, Gauthier BR, Schlegel W, (2007) Transcriptional response of pancreatic beta cells to metabolic stimulation: large scale identification of immediate-early and secondary response genes. BMC Mol Biol, 8: 54. doi:10.1186/1471-2199-8-54. PubMed: 17587450.
12. Wagner K-D, Wagner N, (2010) Peroxisome proliferator-activated receptor beta/delta (PPARbeta/delta) acts as regulator of metabolism linked to multiple cellular functions. Pharmacol Ther, 125: 423-435. doi:10.1016/j.pharmthera.2009.12.001. PubMed: 20026355.
13. Zhang H, Pi R, Li R, Wang P, Tang F, et al. (2007) PPARbeta/delta activation inhibits angiotensin II-induced collagen type I expression in rat cardiac fibroblasts. Arch Biochem Biophys, 460: 25-32. doi:10.1016/j.abb.2007.01.028. PubMed: 17346664.
14. Ostenson C-G, Efendic S, (2007) Islet gene expression and function in type 2 diabetes; studies in the Goto-Kakizaki rat and humans. Diabetes Obes Metab, 9 (Suppl 2):: 180-186. doi:10.1111/j.1463-1326.2007.00787.x. PubMed: 17919192.
15. Tahara A, Matsuyama-Yokono A, Nakano R, Someya Y, Hayakawa M, et al. (2009) Antihyperglycemic effects of ASP8497 in streptozotocin-nicotinamide induced diabetic rats: comparison with other dipeptidyl peptidase-IV inhibitors. Pharmacol Rep, 61: 899-908. PubMed: 19904014.
16. Orskov C, Holst JJ, (1987) Radio-immunoassays for glucagon-like peptides 1 and 2 (GLP-1 and GLP-2). Scand J Clin Lab Invest, 47: 165-174. doi:10.3109/00365518709168885. PubMed: 3576119.
17. Escudero EM, Camilión de Hurtado MC, Pérez NG, Tufare AL, (2004) Echocardiographic assessment of left ventricular midwall mechanics in spontaneously hypertensive rats. Eur J Echocardiogr, 5: 169-175. doi:10.1016/j.euje.2003.11.004. PubMed: 15147658.
18. Ravassa S, Zudaire A, Carr RD, Díez J, (2011) Antiapoptotic effects of GLP-1 in murine HL-1 cardiomyocytes. Am J Physiol Heart Circ Physiol, 300: H1361-H1372. doi:10.1152/ajpheart.00885.2010. PubMed: 21278133.
19. Claycomb WC, Lanson NA, Stallworth BS, Egeland DB, Delcarpio JB, et al. (1998) HL-1 cells: A cardiac muscle cell line that contracts and retains phenotypic characteristics of the adult cardiomyocyte. Proc Natl Acad Sci U S A, 95: 2979-2984. doi:10.1073/pnas.95.6.2979. PubMed: 9501201.
20. Martín R, Miana M, Jurado-López R, Martínez-Martínez E, Gómez-Hurtado N, et al. (2012) DIOL triterpenes block profibrotic effects of angiotensin II and protect from cardiac hypertrophy. PLOS ONE. 7(7):: e41545. PubMed: 22844495.
21. Strutz F, Okada H, Lo CW, Danoff T, Carone RL, et al. (Jul(1995) Identification and characterization of a fibroblast marker: FSP1. J Cell Biol Jul;130(2):: 393-405. doi:10.1083/jcb.130.2.393. PubMed: 7615639.
22. Hickson-Bick DLM, Sparagna GC, Buja LM, McMillin JB, (2002) Palmitate-induced apoptosis in neonatal cardiomyocytes is not dependent on the generation of ROS. Am J Physiol Heart Circ Physiol, 282: H656-H664. PubMed: 11788415.
23. Ishibashi Y, Matsui T, Takeuchi M, Yamagishi S, (2011) Sitagliptin augments protective effects of GLP-1 against advanced glycation end product receptor axis in endothelial cells. Horm Metab Res, 43: 731-734. doi:10.1055/s-0031-1284383. PubMed: 21932180.
24. Ares-Carrasco S, Picatoste B, Camafeita E, Carrasco-Navarro S, Zubiri I, et al. (2012) Proteome changes in the myocardium of experimental chronic diabetes and hypertension: Role of PPARα in the associated hypertrophy. J Proteomics, 75: 1816-1829. doi:10.1016/j.jprot.2011.12.023. PubMed: 22234359.
25. Dhillon S, (2010) Sitagliptin: a review of its use in the management of type 2 diabetes mellitus. Drugs, 70: 489-512. doi:10.2165/11203790-000000000-00000. PubMed: 20205490.
26. Mojsov S, Heinrich G, Wilson IB, Ravazzola M, Orci L, et al. (1986) Preproglucagon gene expression in pancreas and intestine diversifies at the level of post-translational processing. J Biol Chem, 261: 11880-11889. PubMed: 3528148.
27. Ye Y, Keyes KT, Zhang C, Perez-Polo JR, Lin Y, et al. (2010) The myocardial infarct size-limiting effect of sitagliptin is PKA-dependent, whereas the protective effect of pioglitazone is partially dependent on PKA. Am J Physiol Heart Circ Physiol, 298: H1454-H1465. doi:10.1152/ajpheart.00867.2009. PubMed: 20207816.
28. Anagnostis P, Athyros VG, Adamidou F, Panagiotou A, Kita M, et al. (2011) Glucagon-like peptide-1-based therapies and cardiovascular disease: looking beyond glycaemic control. Diabetes Obes Metab, 13: 302-312. doi:10.1111/j.1463-1326.2010.01345.x. PubMed: 21205117.
29. Noyan-Ashraf MH, Momen MA, Ban K, Sadi A-M, Zhou Y-Q, et al. (2009) GLP-1R agonist liraglutide activates cytoprotective pathways and improves outcomes after experimental myocardial infarction in mice. Diabetes, 58: 975-983. doi:10.2337/db08-1193. PubMed: 19151200.
30. Yan W, Zhang H, Liu P, Wang H, Liu J, et al. (2013) Impaired mitochondrial biogenesis due to dysfunctional adiponectin-AMPK-PGC-1α signaling contributing to increased vulnerability in diabetic heart. Basic Res Cardiol, 108: 329. doi:10.1007/s00395-013-0329-1. PubMed: 23460046.
31. Rajesh M, Mukhopadhyay P, Bátkai S, Patel V, Saito K, et al. (2010) Cannabidiol attenuates cardiac dysfunction, oxidative stress, fibrosis, and inflammatory and cell death signaling pathways in diabetic cardiomyopathy. J Am Coll Cardiol, 56: 2115-2125. doi:10.1016/j.jacc.2010.07.033. PubMed: 21144973.
32. Ares-Carrasco S, Picatoste B, Benito-Martín A, Zubiri I, Sanz AB, et al. (2009) Myocardial fibrosis and apoptosis, but not inflammation, are present in long-term experimental diabetes. Am J Physiol Heart Circ Physiol, 297: H2109-H2119. doi:10.1152/ajpheart.00157.2009. PubMed: 19820199.
33. D'Souza A, Howarth FC, Yanni J, Dobryznski H, Boyett MR, et al. (2011) Left Ventricle Structural Remodelling in the Prediabetic Goto-Kakizaki Rat. Exp Physiol 96(9):: 875-888. PubMed: 21622965.
34. Lorell BH, Carabello BA, (Jul 25(2000) Left ventricular hypertrophy: pathogenesis, detection, and prognosis. Circulation Jul 25;102(4):: 470-479. doi:10.1161/01.CIR.102.4.470. PubMed: 10908222.
35. Regan TJ, (1983) Congestive heart failure in the diabetic. Annu Rev Med, 34: 161-168. doi:10.1146/annurev.me.34.020183.001113. PubMed: 6344754.
36. Lenski M, Kazakov A, Marx N, Böhm M, Laufs U, (2011) Effects of DPP-4 inhibition on cardiac metabolism and function in mice. J Mol Cell Cardiol, 51: 906-918. doi:10.1016/j.yjmcc.2011.08.001. PubMed: 21871459.
37. Rendell M, Drincic A, Andukuri R, (2012) Alogliptin benzoate for the treatment of type 2 diabetes. Expert Opin Pharmacother, 13: 553-563. doi:10.1517/14656566.2012.656088. PubMed: 22296609.
38. Rosenstock J, Sankoh S, List JF, (2008) Glucose-lowering activity of the dipeptidyl peptidase-4 inhibitor saxagliptin in drug-naive patients with type 2 diabetes. Diabetes Obes Metab, 10: 376-386. doi:10.1111/j.1463-1326.2008.00876.x. PubMed: 18355324.
39. Mellitzer G, Gradwohl G, (2011) Enteroendocrine cells and lipid absorption. Curr Opin Lipidol, 22: 171-175. doi:10.1097/MOL.0b013e32834622a2. PubMed: 21464713.
40. Cobble M, (2012) Differentiating among incretin-based therapies in the management of patients with type 2 diabetes mellitus. Diabetology & Metabolic Syndrome, 4:8.
41. Sauvé M, Ban K, Momen MA, Zhou Y-Q, Henkelman RM, et al. (2010) Genetic deletion or pharmacological inhibition of dipeptidyl peptidase-4 improves cardiovascular outcomes after myocardial infarction in mice. Diabetes, 59: 1063-1073. doi:10.2337/db09-0955. PubMed: 20097729.
42. Ishibashi Y, Matsui T, Ojima A, Nishino Y, Nakashima S, et al. (2012) Glucagon-like peptide-1 inhibits angiotensin II-induced mesangial cell damage via protein kinase A. Microvasc Res;84(3):: 395-398. doi:10.1016/j.mvr.2012.06.008. PubMed: 22750392.
43. Mima A, Hiraoka-Yamomoto J, Li Q, Kitada M, Li C, et al. (. Nov(2012) Protective effects of GLP-1 on glomerular endothelium and its inhibition by PKCβ activation in diabetes. Diabetes. Nov;61(11):: 2967-2979. doi:10.2337/db11-1824. PubMed: 22826029.
44. Read PA, Khan FZ, Heck PM, Hoole SP, Dutka DP, (2010) DPP-4 inhibition by sitagliptin improves the myocardial response to dobutamine stress and mitigates stunning in a pilot study of patients with coronary artery disease. Circ Cardiovasc Imaging, 3: 195-201. doi:10.1161/CIRCIMAGING.109.899377. PubMed: 20075143.
45. Gros R, You X, Baggio LL, Kabir MG, Sadi AM, et al. (2003) Cardiac function in mice lacking the glucagon-like peptide-1 receptor. Endocrinology, 144: 2242-2252. doi:10.1210/en.2003-0007. PubMed: 12746281.
46. Tomas E, Habener JF, (2010) Insulin-like actions of glucagon-like peptide-1: a dual receptor hypothesis. Trends Endocrinol Metab 21: 59-67. doi:10.1016/j.tem.2009.11.007. PubMed: 20018525.
47. Wang X-F, Zhang J-Y, Li L, Zhao X-Y, (2011) Beneficial effects of metformin on primary cardiomyocytes via activation of adenosine monophosphate-activated protein kinase. Chin Med J (Engl), 124: 1876-1884. PubMed: 21740847.
48. Xiao H, Ma X, Feng W, Fu Y, Lu Z, et al. (2010) Metformin attenuates cardiac fibrosis by inhibiting the TGFbeta1-Smad3 signalling pathway. Cardiovasc Res, 87: 504-513. doi:10.1093/cvr/cvq066. PubMed: 20200042.
49. Okerson T, Chilton RJ, (2010) The Cardiovascular Effects of GLP-1 Receptor Agonists. Cardiovasc Ther.
50. Oeseburg H, De Boer RA, Buikema H, Van der Harst P, Van Gilst WH, et al. (2010) Glucagon-like peptide 1 prevents reactive oxygen species-induced endothelial cell senescence through the activation of protein kinase A. Arterioscler Thromb Vasc Biol, 30: 1407-1414. doi:10.1161/ATVBAHA.110.206425. PubMed: 20448207.
51. Burns KA, Vanden Heuvel JP, (2007) Modulation of PPAR activity via phosphorylation. Biochim Biophys Acta, 1771: 952-960. doi:10.1016/j.bbalip.2007.04.018. PubMed: 17560826.
52. Wagner N, Jehl-Piétri C, Lopez P, Murdaca J, Giordano C, et al. (2009) Peroxisome proliferator-activated receptor beta stimulation induces rapid cardiac growth and angiogenesis via direct activation of calcineurin. Cardiovasc Res, 83: 61-71. doi:10.1093/cvr/cvp106. PubMed: 19351742.
53. Fan SC, Yu BC, Chen ZC, Chen LJ, Chung HH, et al. (2010) The decreased expression of peroxisome proliferator-activated receptors delta (PPARdelta) is reversed by digoxin in the heart of diabetic rats. Horm Metab Res, 42: 637-642. doi:10.1055/s-0030-1253373. PubMed: 20446238.
54. Kim HJ, Kim MY, Jin H, Kim HJ, Kang SS, et al. (2009) Peroxisome proliferator-activated receptor {delta} regulates extracellular matrix and apoptosis of vascular smooth muscle cells through the activation of transforming growth factor-{beta}1/Smad3. Circ Res, 105: 16-24. doi:10.1161/CIRCRESAHA.108.189159. PubMed: 19461048.
55. Piteau S, Olver A, Kim S-J, Winter K, Pospisilik JA, et al. (2007) Reversal of islet GIP receptor down-regulation and resistance to GIP by reducing hyperglycemia in the Zucker rat. Biochem Biophys Res Commun, 362: 1007-1012. doi:10.1016/j.bbrc.2007.08.115. PubMed: 17803965.